NARCOLEPSY TYPE 1

This study tests whether HBS-301 (pitolisant) can reduce excessive daytime sleepiness and cataplexy (sudden muscle weakness) in adults with narcolepsy. Participants receive either the drug or a placebo for several weeks, followed by an open-label phase where everyone gets the dru…

This study looks at the long-term safety and tolerability of the drug TAK-360 in people with narcolepsy (type 1 or 2) or idiopathic hypersomnia — conditions that cause severe daytime sleepiness. Participants who completed a previous TAK-360 study can join and will continue taking…

This study is a long-term follow-up for people with narcolepsy or idiopathic hypersomnia who previously took the experimental drug ORX750. Researchers want to see if the drug remains safe and effective over time. About 90 participants will take ORX750 orally and be monitored for …

This study is checking the long-term safety of a drug called TAK-861 in 500 people with type 1 narcolepsy who have already taken it in earlier trials. Participants will continue taking TAK-861 tablets, and researchers will monitor for side effects. The goal is to see if the drug …

This study tests an experimental drug called cleminorexton in 222 adults with narcolepsy type 1 or 2. The drug mimics a natural brain protein that helps keep people awake. The goal is to see if it safely reduces daytime sleepiness and improves daily functioning. Participants must…

This study tests a new drug, TAK-360, for adults with narcolepsy type 1, a condition causing severe daytime sleepiness and sudden muscle weakness (cataplexy). About 92 participants will receive either TAK-360 or a placebo to see if the drug is safe and well-tolerated. Participant…

This phase 3 trial tests whether a daily tablet called ALKS 2680 can reduce severe daytime sleepiness and sudden muscle weakness (cataplexy) in adults with narcolepsy type 1. About 150 participants will receive either the drug or a placebo for 12 weeks. The study measures improve…

This early-stage trial is testing a new drug called Lu AH69593 to see if it is safe and how the body handles it. The study includes healthy volunteers and people with narcolepsy. Researchers will monitor side effects and measure drug levels in the blood, including how food affect…

This phase 3 trial tests whether a daily tablet called ALKS 2680 can reduce daytime sleepiness and cataplexy (sudden muscle weakness) in 150 adults with narcolepsy type 1. Participants will take the drug or a placebo for 12 weeks, and researchers will measure changes in sleep tes…

This study tests whether E2086, an oral tablet, can reduce excessive daytime sleepiness in adults with narcolepsy. About 64 participants will receive either the drug or a placebo for 4 weeks. Researchers will measure how long people can stay awake using a standard test, and also …

This study tests a new drug called ORX750 (cleminorexton) in 248 adults with narcolepsy type 1, type 2, or idiopathic hypersomnia—conditions that cause severe daytime sleepiness. The drug mimics a natural brain protein that helps keep people awake. The main goals are to check saf…

This study is testing the long-term safety and how well ALKS 2680 works over time in people with narcolepsy type 1, type 2, or idiopathic hypersomnia. Participants take a once-daily tablet at different doses. The goal is to see if the drug remains safe and effective for staying a…

This study looks at how eating affects sleepiness and nighttime sleep in people with type 1 narcolepsy, idiopathic hypersomnia, and healthy volunteers. Over 4 days, participants will log their meals, wear a glucose monitor, and track sleep with a headband and watch. The goal is t…

This study aims to find out how many people in Spain have been diagnosed with narcolepsy type 1 or type 2, and how many new cases are diagnosed each year. Researchers will review medical records from hospitals across Spain to count patients and understand patterns. No treatment o…

This study looks at pain in people with idiopathic REM sleep behavior disorder (iRBD), a condition that strongly increases the risk of developing Parkinson's disease. Researchers will compare pain levels and patterns between 24 participants with iRBD and a control group with narc…

This study looks at how reliable the Maintenance of Wakefulness Test (MWT) is for people who feel very sleepy during the day. Researchers will test 100 participants twice to see if the results are consistent. If the test proves reliable, it could help doctors decide who is safe t…

This study looks at whether changes in gut bacteria and increased intestinal permeability can trigger inflammation that damages brain cells in people with type 1 narcolepsy. Researchers will collect blood, stool, and spinal fluid samples from 120 participants to measure bacterial…